Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The EGFR-independent activation of the RAS/RAF/MEK/MAPK pathway is one of the resistance mechanisms to cetuximab.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Cancer Res.

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1078-0432

ISSN (Print): 1078-0432

Publication date (Electronic): Jul 15 2014

Volume: 20

Issue: 14

Affiliations

[1 ] Authors' Affiliation: Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale "F. Magrassi e A. Lanzara," Seconda Università degli Studi di Napoli, Via S. Pansini 5, Naples, Italy tessy75@inwind.it.

[2 ] Authors' Affiliation: Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale "F. Magrassi e A. Lanzara," Seconda Università degli Studi di Napoli, Via S. Pansini 5, Naples, Italy.

Article

Publisher Item ID: 1078-0432.CCR-13-2181

DOI: 10.1158/1078-0432.CCR-13-2181

PubMed ID: 24812410

SO-VID: 253bdd9b-73de-443b-bddc-e75c6f8f87ac

History

Data availability:

Comments

Comment on this article

scite_

Cited by 45

See all cited by